The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The usefulness of dogs and monkeys in predicting potential qualitative drug toxicity in man was examined retrospectively for twenty‐five anticancer compounds of diverse chemical and functional classification. It was found that the large animal screen served to alert the physician to a significant proportion of the total spectrum of drug effects, which were encountered during the clinical use of a new toxic compound. The dog and monkey correctly predicted bone marrow depression, gastrointestinal disturbance, and hepatotoxicity for each drug producing these effects in the clinic; in the case of renal, cardiovascular, and neuromuscular toxicity, however, the large animal screen failed in each instance to predict one drug that produced these toxicities in man. The correct predictions were accomplished at the expense of a high percentage of false positives, which resulted from the necessity of using severely toxic dose levels in order to demonstrate all potential toxicities inherent in any compound. While organ system toxicity observed during an animal study can never be disregarded, it should be viewed with an understanding of certain limitations of animal toxicologic data. While toxicity may develop in man in an organ system predicted susceptible by an animal, a different specific clinical or chemical parameter may be involved. The adverse reaction may appear in man at a greater or lesser dose level or may follow a different order of appearance in relationship to the total spectrum of qualitative toxicity inherent in the compound.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Schein present an analysis of 25 anticancer drug toxicities in several papers [83–86], each paper combining the analysis with other information.”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [86]
Citations
Cites
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Self-citationMitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA
Iyer, V. N., & Szybalski, W. (1964) · Science · doi:10.1126/science.145.3627.55 · Cited by 570
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Studies on the Diabetogenic Action of Streptozotocin (NSC37917)
Raikieten, N. (1963) · Medical Entomology and Zoology · Cited by 443
The use of body surface area as a criterion of drug dosage in cancer chemotherapy.
Pinkel, D. P. (1958) · PubMed · Cited by 344
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
Vt, D. V., Pp, C., Owens, A. H., Gold, G. L., Mj, K., & Edmonson, J. H. (1965) · PubMed · Cited by 218
Clinical studies with 5-fluorouracil.
Curreri, A. R., Ansfield, F. J., McIver, F. A., Waisman, H. A., & Heidelberger, C. (1958) · PubMed · Cited by 206
Schein, P. S., Cooney, D. A., & Vernon, M. L. (1967) · PubMed · Cited by 206
Self-citationComparative patterns of drug metabolism.
Williams, R. T. (1967) · PubMed · Cited by 170
A Syllabus of Laboratory Examinations in Clinical Diagnosis
Perry, C. A., Humphrey, J., & Brownlee, M. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.8_pt_1.1010-a · Cited by 159
Cited by
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
“(12) showed that for antineoplastic drugs, lethal doses to 10% (LD10) of rodents and maximum tolerated doses (MTD) in nonrodents correlated with the human MTD when the doses were normalized to the same administration schedule and expressed in terms of BSA in mg/m(2).”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
Hayes' Principles and Methods of Toxicology
(2014) · CRC Press eBooks · doi:10.1201/b17359 · Cited by 280
First dose of potential new medicines to humans: how animals help
Greaves, P., Williams, A., & Eve, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1329 · Cited by 243
“The dog data were better correlated with human adverse effects in the study of 25 anticancer drugs by Schein et al.(16).”
BackgroundTranslating dosages from animal models to human clinical trials—revisiting body surface area scaling
Blanchard, O. L., & Smoliga, J. M. (2015) · The FASEB Journal · doi:10.1096/fj.14-269043 · Cited by 183
“This workhasbeendiscussedbyDixon [1976 (42)] who showed that expressing dosages with BSA or bodymass were similar in their inaccuracies between larger species for calculating toxicity in first-in-human clinical trials (42, 43).”
BackgroundAn analysis of the use of animal models in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182
Models for prevention and treatment of cancer: Problems vs promises
Aggarwal, B. B., Danda, D., Gupta, S., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 179
“Evaluation of effects of 25 anticancer drugs in dogs and monkeys showed only 40% concordance with the results in humans for neurological and neuromuscular toxic effects [38,39] and a concordence of less than 10% for cardiotoxicity.”
Result1,3-Bis(2-Chloroethyl)-1-Nitrosourea (Bcnu) And Other Nitrosoureas In Cancer Treatment: A Review
(1973) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60343-7 · Cited by 168
Self-citationKerlin, R., Bolon, B., Burkhardt, J., Francke, S., Greaves, P., Meador, V., & Popp, J. (2016) · Toxicologic Pathology · doi:10.1177/0192623315623265 · Cited by 135
“Depending on the test system, some adverse effects may correlate well between animals and humans, while biological responses in other systems are correlated poorly (Dorato and Engelhardt 2005; Freireich et al. 1966; Owens 1962; Schein et al. 1970).”
BackgroundAtkins, J. T., George, G. C., Hess, K., Marcelo-Lewis, K. L., Yuan, Y., Borthakur, G., Khozin, S., LoRusso, P., & Hong, D. S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01033-x · Cited by 132
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
Goldsmith, M. A., Slavik, M., & Carter, S. K. (1975) · PubMed · Cited by 134
Self-citationMedical progress depends on animal models - doesn't it?
Matthews, R. A. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2007.070164 · Cited by 132
Schneider, K., Oltmanns, J., & Hassauer, M. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.03.001 · Cited by 123
Dixit, R., & Boelsterli, U. A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.018 · Cited by 121
Interspecific Scaling of Toxicity Data
Travis, C. C., & White, R. K. (1988) · Risk Analysis · doi:10.1111/j.1539-6924.1988.tb01158.x · Cited by 107
Extrapolation of Toxicological and Pharmacological Data from Animals to Humans
Chappell, W. R., & Mordenti, J. J. (1991) · Advances in Drug Research · doi:10.1016/b978-0-12-013320-8.50005-8 · Cited by 116
Opportunities for the replacement of animals in the study of nausea and vomiting
Holmes, A., Rudd, J., Tattersall, F., Aziz, Q., & Andrews, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00176.x · Cited by 86
“The Schein et al. (1970) study compared data from 383 dogs and 153 monkeys with that from >3700 patients receiving the same compounds.”
InfluentialNormalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile?
Reilly, J. J., & Workman, P. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685883 · Cited by 86
Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 81
“The basis for which is primarily the work of Freireich et al. (1966) and Schein et al. (1970), who showed that for antineoplastic drugs, human and animal doses correlate well when scaled by body surface area.”
BackgroundTamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., et al. (2013) · The Journal of Toxicological Sciences · doi:10.2131/jts.38.581 · Cited by 79
Mahmood, I., Green, M. D., & Fisher, J. E. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043007002 · Cited by 73
“For most systemically administered drugs, conversion to the HED is typically based on the normalization of doses to body surface area.(4,5) However, the applicability of the data used to derive this scaling factor (i.”
MethodInterspecies Extrapolation: A Reexamination of Acute Toxicity Data
Watanabe, K. H., Bois, F. Y., & Zeise, L. A. (1992) · Risk Analysis · doi:10.1111/j.1539-6924.1992.tb00677.x · Cited by 69
Toxicity of abrin and ricin in mice and dogs
Fodstad, Ø., Johannessen, J. V., Schjerven, L., & Pihl, A. (1979) · Journal of Toxicology and Environmental Health · doi:10.1080/15287397909529815 · Cited by 68
The ability of animal studies to detect serious post marketing adverse events is limited
van Meer, P. J. K., Kooijman, M., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.09.002 · Cited by 66
“…regulatory authorities rely on animal studies to predict the safety and efficacy of new therapeutics in humans, it is striking that few attempts have been made to demonstrate this predictive ability (Fletcher, 1978; Freireich et al., 1966; Owens, 1962; Rozencweig et al., 1981; Schein et al., 1970).”
Non-human primates in medical research and drug development: a critical review
Bailey, J. (2005) · Biogenic Amines · doi:10.1163/156939105774647385 · Cited by 52
“…does not stand up to statistical scrutiny: much of the evidence supporting the predictive nature of animal toxicity was derived from an earlier study (Schein et al., 1970) with incorrectly calculated false positive and false negative rates (Personal communication from professional statistician).”
BackgroundDose Selection in Preclinical Studies: Cross-Species Dose Conversion
Шекунова, Е. В., Kovaleva, M. А., Макарова, М. Н., & Makarov, V. G. (2020) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2020-10-1-19-28 · Cited by 60
Developing drug prototypes: pharmacology replaces safety and tolerability?
Cohen, A. F. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3227 · Cited by 46
Methods for Identifying a Default Cross-Species Scaling Factor
Rhomberg, L. R., & Lewandowski, T. A. (2006) · Human and Ecological Risk Assessment An International Journal · doi:10.1080/10807030600977269 · Cited by 45
The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma
Lui, J. W., Xiao, S., Ogomori, K., Hammarstedt, J. E., Little, E. C., & Lang, D. (2018) · Journal of Cancer · doi:10.7150/jca.27472 · Cited by 42
“Following prior methods for conversion between mg/m2 to mg per kg of body weight [22, 23], this converts to 0.”
MethodThe Use of the Dog in Toxicity Tests on Pharmaceutical Compounds
Parkinson, C., & GRASSO, P. (1993) · Human & Experimental Toxicology · doi:10.1177/096032719301200202 · Cited by 40
Problems in Extrapolating Toxicity Data for Laboratory Animals to Man
Dixon, R. L. (1976) · Environmental Health Perspectives · doi:10.1289/ehp.761343 · Cited by 35
Barriers to Efficient Development of Cancer Therapeutics
Schein, P. S., & Scheffler, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0329 · Cited by 33
Self-citationCooney, D. A., & Rosenbluth, R. J. (1975) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60222-7 · Cited by 33
Marlowe, J. L., Akopian, V., Karmali, P. P., Kornbrust, D. J., Lockridge, J. A., & Semple, S. C. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0671 · Cited by 36
“Resulting publications demonstrated that direct extrapolation from the body weight-relative MTD underpredicted human sensitivity and that better correlation of MTDs across species was obtained by expressing doses per BSA [36,37].”
Price, P. S., Keenan, R. E., & Swartout, J. C. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.03.026 · Cited by 31
Gastrointestinal safety pharmacology in drug discovery and development
Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_12 · Cited by 29
Toxicology screening in small animals
Bradner, W. T., & Schurig, J. E. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80029-1 · Cited by 29
A Historical View and Vision into the Future of the Field of Safety Pharmacology
Bass, A. S., Hombo, T., Kasai, C., Kinter, L. B., & Valentin, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_1 · Cited by 31
Bennett, R. P., Finch, C. L., Postnikova, E. N., Stewart, R. A., Caì, Y., Yú, S., Liang, J. Y., Dyall, J., Salter, J. D., Smith, H. C., et al. (2020) · Viruses · doi:10.3390/v13010052 · Cited by 24
A quantitative risk assessment for fumonisins B1and B2in US corn
Humphreys, S. H., Carrington, C. D., & Bolger, M. (2001) · Food Additives & Contaminants · doi:10.1080/02652030010021486 · Cited by 24
Interspecies Scaling of Anesthetic Potency
Travis, C. C., & Bowers, J. C. (1991) · Toxicology and Industrial Health · doi:10.1177/074823379100700402 · Cited by 23
Proposal of new uncertainty factor application to derive tolerable daily intake
Hasegawa, R., Hirata‐Koizumi, M., Dourson, M. L., Parker, A., Sweeney, L. M., Nishikawa, A., Yoshida, M., Ono, A., & Hirose, A. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.06.006 · Cited by 23
“(2004) extracted correlated human and animal data sets for 63 anti-cancer drugs from six additional publications (Goldsmith et al., 1975; Schein et al., 1979; Travis and White, 1988; Rozencweig et al., 1981; Grieshaber and Marsoni, 1986; Paxton et al., 1990) to demonstrate that caloric demand scaling was a suitable ad…”
BackgroundMonro, A. M., & Mehta, D. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80002-6 · Cited by 22
General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe
(1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90244-n · Cited by 21
Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties
Bennett, R. P., Postnikova, E. N., Eaton, B., Caì, Y., Yú, S., Smith, C. O., Liang, J. Y., Zhou, H., Kocher, G. A., Murphy, M. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.153165 · Cited by 23
“Preclinical work archived at the NCI revealed that sangivamycin was tested in grivets and was tolerated for 10 days at 1.6 mg/kg/d (total dose 16 mg/kg) and 28 days at 0.4 mg/kg/d (total dose 11.2 mg/kg) (41).”
InfluentialPaxton, J. W. (1995) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1995.tb01949.x · Cited by 20
Foster, B. J., Newell, D. R., Gumbrell, L. A., Calvert, H., Graham, M. A., Kaye, S. B., & Jenns, K. (1992) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80077-2 · Cited by 20
Posvar, E. L., & Sedman, A. J. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03262.x · Cited by 19
Interspecies extrapolation based on the RepDose database—A probabilistic approach
Escher, S. E., Batke, M., Hoffmann-Doerr, S., Messinger, H., & Mangelsdorf, I. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.01.027 · Cited by 18
Present status of cancer chemotherapy
Zubrod, C. G. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90070-8 · Cited by 18
The Case for a New National Program for the Development of Cancer Therapeutics
Schein, P. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3142 · Cited by 17
Self-citationPreclinical evaluation and phase I trials
Judson, I. R. (1992) · Cancer biology and medicine · doi:10.1007/978-94-009-0385-2_8 · Cited by 17
Correlation of Human Hepatotoxicants with Hepatic Damage in Animals
Hayes, A. W., Fedorowski, T., Balázs, T., Carlton, W. W., Fowler, B. A., GILMAN, M. R., HEYMAN, I., JACKSON, B. A., Kennedy, G. L., Shapiro, R., et al. (1982) · Toxicological Sciences · doi:10.1093/toxsci/2.2.55-b · Cited by 17
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00008-7 · Cited by 18
Data Processing and Interpretation
Evans, G. O. (2008) · CRC Press eBooks · doi:10.1201/9781420080100-14 · Cited by 16
Pharmacological vs. classical approaches in the design of first in man clinical drug trials
van den Bogert, C. A., Cohen, A. F., Leufkens, H. G. M., & van Gerven, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13422 · Cited by 13
M.A., H. J. C. I., & Fuchsman, P. C. (2023) · Integrated Environmental Assessment and Management · doi:10.1002/ieam.4842 · Cited by 16
“The agency also evaluated evidence for allometric scaling of toxicity in mammals, derived from studies of repeated ‐ dose toxicity of anticancer agents (Freireich et al., 1966; Schein et al., 1970).”
BackgroundAhuja, V., Bokan, S., & Sharma, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.007 · Cited by 14
Byles, P. H., Dobkin, A. B., & Jones, D. B. (1971) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03025691 · Cited by 13
Clark, R. L. (2017) · Birth Defects Research · doi:10.1002/bdr2.1035 · Cited by 15
“The Roche postmarketing surveillance database was subsequently updated and evaluated again with a cutoff date of October 26, 2010 (Schlagenhauf et al., 2012a,b).”
MethodHaemopoietic and Lymphatic Systems
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50005-5 · Cited by 12
Byles, P. H., Dobkin, A. B., Ferguson, J. H., & Levy, A. A. (1971) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03025690 · Cited by 12
The National Program for Cancer Chemotherapy
Zubrod, C. G. (1972) · JAMA · doi:10.1001/jama.1972.03210090041011 · Cited by 12
Problems in Predicting Drug Effects across Species Lines
Smith, C. G., Poutsiaka, J. W., & Schreiber, E. C. (1973) · Journal of International Medical Research · doi:10.1177/030006057300100601 · Cited by 12
Tissue Dosimetry for Reactive Metabolites
Travis, C. C. (1990) · Risk Analysis · doi:10.1111/j.1539-6924.1990.tb01052.x · Cited by 11
Tomaszewski, J. E., Smith, A. C., Covey, J. M., Donohue, S. J., Rhie, J. K., & Schweikart, K. M. (2002) · Elsevier eBooks · doi:10.1016/b978-012072651-6/50018-8 · Cited by 13
Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies
Valentin, J., Keisu, M., & Hammond, T. G. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse203 · Cited by 11
Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester
Clark, R. L. (2020) · Birth Defects Research · doi:10.1002/bdr2.1798 · Cited by 12
Tissue distribution of [14C]methyl mercury in the lobster,Homarus americanus
Guarino, A. M., Anderson, J. B., Pritchard, J. B., & Rall, D. P. (1976) · Journal of Toxicology and Environmental Health · doi:10.1080/15287397609529413 · Cited by 10
Self-citationRajasekaran, U., & Nayak, K. (2014) · Cited by 10
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50008-0 · Cited by 10
Hemopoietic and Lymphatic Systems
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00004-x · Cited by 12
Developmental toxicity studies of lumefantrine and artemether in rats and rabbits
Clark, R. L., Youreneff, M., & DeLise, A. M. (2016) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21189 · Cited by 11
On the Use of 0.75 as an Interspecies Scaling Factor12
Travis, C. C., & Morris, J. (1992) · Risk Analysis · doi:10.1111/j.1539-6924.1992.tb00678.x · Cited by 9
Igwemezie, L. N., Kaul, S., & Barbhaiya, R. H. (1995) · Pharmaceutical Research · doi:10.1023/a:1016203107497 · Cited by 9
Predicting the Safety of Medicines from Animal Toxicity Tests II. Rodents and Non-Rodents
Lumley, C. E., & Walker, S. (1987) · Springer eBooks · doi:10.1007/978-3-642-72558-6_57 · Cited by 9
Mechanisms and Models in Toxicology
Chambers, C. M., Chambers, P. L., & Davies, D. S. (1987) · Springer eBooks · doi:10.1007/978-3-642-72558-6 · Cited by 9
Eddleston, M. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2105709 · Cited by 10
The safety of Osmanthus fragrans ethanol extract treatment in BALB/c mice
Hung, C., Lin, C., Li, K.-Y., Hung, T., & Huang, F.-L. (2013) · International Journal of Pharmacology and Toxicology · doi:10.14419/ijpt.v2i1.1426 · Cited by 8
“The evaluation of animal toxicity screening systems can be used as a tool to enable safe introduction of new drugs into humans, although the authors of those studies did not attempt to relate therapeutic doses in various species (Freireich et al. 1966, Schein et al. 1970).”
Nervous System and Special Sense Organs
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50015-8 · Cited by 8
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00007-5 · Cited by 9
The Phase I Study: General Objectives, Methods, and Evaluation
Bodey, G. P., & Legha, S. S. (1987) · Springer eBooks · doi:10.1007/978-1-4613-2317-4_8 · Cited by 8
Interspecies Extrapolation of Toxicity Data1
Goddard, M., & Krewski, D. R. (1992) · Risk Analysis · doi:10.1111/j.1539-6924.1992.tb00679.x · Cited by 8
Carter, S. K., & Goldsmith, M. A. (1974) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-49306-5_9 · Cited by 7
Self-citationSchaeppi, U. H., & Hess, R. (1984) · Inflammation Research · doi:10.1007/bf01966846 · Cited by 7
Cerebral Baylisascaris larva migrans in a cynomolgus macaque (Macaca fascicularis)
Shoieb, A. M., & Radi, Z. A. (2014) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2014.03.004 · Cited by 6
Toxicology of environmental agents: a blend of applied and basic research.
Dixon, R. L. (1972) · Environmental Health Perspectives · doi:10.1289/ehp.7202103 · Cited by 6
Nervous System and Special Sense Organs
Greaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00014-2 · Cited by 6
Candidate Drugs for Carcinogenic Property Studies: Procedures
Rall, D. P. (1975) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1975.tb01421.x · Cited by 6
Self-citationDose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose
Modi, M. (2006) · Springer eBooks · doi:10.1007/0-387-33706-7_3 · Cited by 6
New Anticancer Drug Design: Past and Future Strategies
Apple, M. A. (1977) · Springer eBooks · doi:10.1007/978-1-4615-6628-1_20 · Cited by 7
Interspecific Scaling of Toxicity Data: A Question of Interpretation
Chappell, W. R. (1989) · Risk Analysis · doi:10.1111/j.1539-6924.1989.tb01211.x · Cited by 6
Boogaard, P. J., Banton, M. I., Dalbey, W. E., Hedelin, A., Riley, A. J., Rushton, E. K., Vaissière, M., & Minsavage, G. D. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2011.11.016 · Cited by 5
The Limitations of Animal Studies: What Can and Cannot Be Predicted for Man
Dayan, A. D. (1991) · Drug Information Journal · doi:10.1177/009286159102500202 · Cited by 5
“(7) analysis of 25 potential anticancer drugs.”
The Toxicologic Evaluation of Marcellomycin—An Antineoplastic Anthracycline Antibiotic
Buroker, E. A., Johnson, D. F., Comereski, C. R., Hirth, R. S., Madissoo, H., & Hottendorf, G. H. (1983) · Drug and Chemical Toxicology · doi:10.3109/01480548309072460 · Cited by 5
Predicting the Safety of Medicines from Animal Toxicity Tests I. Rodents Alone
Lumley, C. E., & Walker, S. (1987) · Springer eBooks · doi:10.1007/978-3-642-72558-6_56 · Cited by 5
Animal Models of Disease for Future Toxicity Predictions
Morgan, S. J., & Elangbam, C. S. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch18 · Cited by 8
Safety Pharmacology: Past, Present, and Future
Hammond, T. G., & Valentin, J. (2006) · Informa Healthcare eBooks · doi:10.1201/9781420004236.ch13 · Cited by 4
Haemopoietic and Lymphatic Systems
Greaves, P. (2000) · Elsevier eBooks · doi:10.1016/b978-044450514-9/50003-6 · Cited by 4
Metadata
- Authors
- Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Newman, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1970-01
- Volume
- 11
- Issue
- 1
- Pages
- 3-40
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415622130
- Cited by
- 146
- References
- 53
- Citations by year
- 2024: 1 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- anticancer agents, drug toxicity prediction, dogs, monkeys, bone marrow depression, hepatotoxicity, gastrointestinal toxicity, nephrotoxicity, cardiotoxicity, neuromuscular toxicity, false positives, animal-to-human extrapolation, adverse drug reactions
- MeSH terms
- Animals, Haplorhini, Antimetabolites, Antineoplastic Agents, Bone Marrow Diseases, Cardiovascular Diseases, Dogs, Eye Manifestations, Gastrointestinal Diseases, Humans, Kidney Diseases, Lymphatic Diseases, Lymphopenia, Methods, Neurologic Manifestations, Respiratory Tract Diseases, Skin Manifestations, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.